NRG GU007 / CGUP19100 Androgen Deprivation Therapy in high risk Prostate cancerResearch Question:
What are the side effects and best dose of the drug, niraparib, in treating patients
with prostate cancer that has a high chance of coming back (high risk)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase II trial studies the side effects and best dose of niraparib, and to see
how well it works in combination with standard of care radiation therapy and hormonal
therapy (androgen deprivation therapy) in treating patients with prostate cancer that
has a high chance of coming back (high risk). Niraparib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Adding niraparib to
the usual treatments of radiation therapy and hormonal therapy may lower the chance
of prostate cancer growing or returning.
Study Reference #: CGUP19100
Lead Researcher (Principal Investigator)
Study Contact Information
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search